On behalf of the Board of Directors, management, and employees of Outlook Therapeutics, I want to extend my deepest gratitude ...

ISELIN, N.J. - Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company with a current market capitalization of $50.3 million, announced the appointment of Faisal G. Sukhtian as Chairman ...

Outlook Therapeutics ( ($OTLK) ) has provided an update. On January 31, 2025, Outlook Therapeutics entered into a Securities Purchase Agreement ...

ISELIN, N.J., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United ...

Outlook Therapeutics Inc (OTLK) stock saw a decline, ending the day at $2.19 which represents a decrease of $-0.11 or -4.78% from the prior close of $2.3. The stock opened at $2.13 and touched a low ...

Outlook Therapeutics Inc (OTLK) stock saw a modest uptick, ending the day at $2.23 which represents a slight increase of $0.04 or 1.83% from the prior close of $2.19. The stock opened at $2.19 and ...

Outlook Therapeutics (OTLK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Douglas ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

Short interest in Outlook Therapeutics Inc (NASDAQ:OTLK) decreased during the last reporting period, falling from 4.13M to 3.51M. This put 21.82% of the company's publicly available shares short.

OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earli ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...